ClinicalTrials.gg
CompletedNCT01929031Updated Nov 16, 2016Results posted

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

A Phase 3 interventional study of ibuprofen + caffeine and ibuprofen in Pain, Postoperative and Tooth Diseases, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-11-16.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
562
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies testing ibuprofen in Pain, Postoperative — 7 open to participants now, 8 under way, none of them phase 3. Ibuprofen · Pain, Postoperative.

Enrollment
5th of 56
562 · median 100
Started
2013
with 2 others
Phase 3
7 of 56
none open now
Registered
8th of 56
by date

Among the 56 studies testing ibuprofen in Pain, Postoperative, this one is the 5th largest by enrollment, is one of 3 that started in 2013, is one of 7 in phase 3, and was the 8th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 56 studies testing ibuprofen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing ibuprofen in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of a combination product containing ibuprofen 400 mg and caffeine 100 mg versus either ingredient alone as well as placebo for the treatment of post-surgical dental pain over an eight-hour period followed by a single dose of study medication (study stage 1). A secondary objective is to evaluate efficacy of multiple doses of the combination in comparison to ibuprofen alone over a 5-day post-surgical period (study stage 2).

03

Conditions studied

  • Pain, Postoperative
  • Tooth Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18 to 55 years of age;
  • Outpatients scheduled to undergo surgical extraction of 3-4 impacted third molar(s), with a minimum of two mandibular extractions. The two mandibular third molars may be partial bony impactions or full bony impactions (as long as the trauma rating is not severe and the surgeons do not feel the subject will have extreme post-surgical pain) OR there may be a combination of one full bony impaction with the second mandibular being a soft tissue impaction or partial bony impaction. Maxillary third molars (or supernumerary teeth) of any type can be extracted;
  • Use of only the following preoperative medication(s)/ anesthetic(s): topical benzocaine, short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide;
  • Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
  • Examined by the attending oral surgeon or physician and medically cleared to participate in the study;
  • Scheduled to undergo a qualifying surgical procedure;
  • In good general health, with a of 30 or less, and have no to any of the study medications or anesthetic drugs;
  • Subjects have at least a categorical pain score of moderate and a numerical rating scale (NRS) score of 5 or greater within 4.5 hours from the time of the last suture.

Exclusion criteria

Exclusion criteria:

  • Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, hyper- or hypothyroidism);
  • Use of a prescription or non-prescription drug with which the administration of ibuprofen or any other non steroidal anti inflammatory or caffeine is ;
  • Acute local infection at the time of surgery that could confound the post-surgical evaluation;
  • Females who are pregnant, lactating, of , or for less than 2 years and not using a medically approved method of (i.e., oral, transdermal, intravaginal or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
  • Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
  • History of alcoholism or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Subjects who are taking central nervous system or other psychotropic drugs (including St. Johns Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
  • Habituation to analgesic drugs or caffeine (i.e., routine use of oral analgesics 5 or more times per week or ingestion of 4 or more caffeine-containing drinks daily); use of "high energy" drinks more than once per week;
  • Use of any type of systemic within the past 30 days or a history of current or previous use of anabolic steroids;
  • History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to acetaminophen, ibuprofen, naproxen, aspirin, celecoxib, or any other non steroidal anti inflammatory or caffeine;
  • Prior use of any type of analgesic or non steroidal anti inflammatory within 5 half-lives of that drug before surgery, except for pre-anesthetic medication and anesthesia for the procedure;
  • Ingestion of any caffeine-containing beverages, chocolate, or alcohol 6 hours or less before surgery;
  • Has impaired liver function, e.g., serum , aspartate aminotransferase, alkaline phosphatase, or Gamma-glutamyltransferase greater than 2.5 times the , or blood urea nitrogen, creatinine, or greater than 1.5 times the upper limit of normal without a known benign explanation;
  • Has known history of a positive antibody test or known HIV infection;
  • Has a known history of or C;
  • Has a abnormal (ECG) at screening as determined by the Investigator:
  • Has taken an product within the past 30 days;
  • Has previously been entered into this study;
  • The subject is a member of the study site staff either directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study or Sponsor.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
562 participants (actual)

Study arms

  • Other
    Caffeine-Ibuprofen

    Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator

    Drug: ibuprofen · Drug: caffeine

  • Other
    Placebo-Ibuprofen/Caffeine

    Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental

    Drug: ibuprofen + caffeine · Drug: placebo

  • Other
    Ibuprofen/Caffeine-Ibuprofen/Caffeine

    Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental

    Drug: ibuprofen + caffeine

  • Other
    Ibuprofen-Ibuprofen

    Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator

    Drug: ibuprofen

  • Other
    Caffeine-Ibuprofen/Caffeine

    Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental

    Drug: caffeine · Drug: ibuprofen + caffeine

  • Other
    Placebo-Ibuprofen

    Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator

    Drug: placebo · Drug: ibuprofen

Interventions

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)

    SPRID0-8h: Time-weighted sum of PAR and PID from 0 to 8 hours, score range: -40 (worst) to 112 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5,2,3,4,5, 6,7 and 8 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 8 were considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 8 hours.

    Time frame: 0 to 8 hours

Secondary outcomes

  1. Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)

    SPRID0-2h: Time-weighted sum of PAR and PID from 0 to 2 hours, score range: -10 (worst) to 28 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5 and 2 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 2 was considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 2 hours.

    Time frame: 0 to 2 hours

  2. Duration of Pain Relief

    Duration of pain relief was defined as the time between the administration of first dose of trial medication and first dose of rescue medication or second dose of trial medication, whichever was first. Duration of pain relief was censored at 8 hours.

    Time frame: 8 hours

  3. Time to Meaningful Pain Relief

    Time to meaningful pain relief was captured by a stopwatch, which was started by the study staff immediately after the administration of the first dose of trial medication and which was to be stopped by the patient as soon as he/she felt meaningful pain relief. Time to meaningful pain relief was censored at 8 hours.

    Time frame: 8 hours

07

Results

Posted Nov 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneIbuprofen/Caffeine - Ibuprofen/CaffeineIbuprofen - IbuprofenCaffeine - Ibuprofen/CaffeineCaffeine - IbuprofenPlacebo - Ibuprofen/CaffeinePlacebo - Ibuprofen
Started21320935353436
Completed20920734353335
Not completed421011
Withdrew: Adverse event311000
Withdrew: Protocol violation100001
Withdrew: Reason other than specified above010010

Outcome measures

PrimaryTime-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)

SPRID0-8h: Time-weighted sum of PAR and PID from 0 to 8 hours, score range: -40 (worst) to 112 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5,2,3,4,5, 6,7 and 8 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 8 were considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 8 hours.

Time frame:
0 to 8 hours
Reported as:
Least squares mean · units on a scale
Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)
units on a scalePlaceboCaffeineIbuprofenIbuprofen/Caffeine
Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)10.554 ± 3.52715.824 ± 3.52540.165 ± 2.04752.291 ± 2.027
Statistical analysis
  • Placebo vs Ibuprofen/Caffeine · ANCOVA · p = <0.0001 · Mean difference (final values): 41.738 · 95% CI 33.767 to 49.708Ibuprofen/Caffeine vs. Placebo
  • Caffeine vs Ibuprofen/Caffeine · ANCOVA · p = <0.0001 · Mean difference (final values): 36.467 · 95% CI 28.497 to 44.437Ibuprofen/Caffeine vs. Caffeine
  • Ibuprofen vs Ibuprofen/Caffeine · ANCOVA · p = <0.0001 · Mean difference (final values): 12.126 · 95% CI 6.493 to 17.759Ibuprofen/Caffeine vs. Ibuprofen
SecondaryTime-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)

SPRID0-2h: Time-weighted sum of PAR and PID from 0 to 2 hours, score range: -10 (worst) to 28 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5 and 2 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 2 was considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 2 hours.

Time frame:
0 to 2 hours
Reported as:
Least squares mean · units on a scale
Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)
units on a scalePlaceboCaffeineIbuprofenIbuprofen/Caffeine
Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)2.059 ± 0.7032.612 ± 0.7026.990 ± 0.40810.584 ± 0.404
Statistical analysis
  • Placebo vs Ibuprofen/Caffeine · ANCOVA · p = <0.0001 · Mean difference (final values): 8.525 · 95% CI 6.937 to 10.113Ibuprofen/Caffeine vs. Placebo
  • Caffeine vs Ibuprofen/Caffeine · ANCOVA · p = <0.0001 · Mean difference (final values): 7.972 · 95% CI 6.384 to 9.559Ibuprofen/Caffeine vs. Caffeine
  • Ibuprofen vs Ibuprofen/Caffeine · ANCOVA · p = <0.0001 · Mean difference (final values): 3.594 · 95% CI 2.472 to 4.716Ibuprofen/Caffeine vs. Ibuprofen
SecondaryDuration of Pain Relief

Duration of pain relief was defined as the time between the administration of first dose of trial medication and first dose of rescue medication or second dose of trial medication, whichever was first. Duration of pain relief was censored at 8 hours.

Time frame:
8 hours
Reported as:
Median · hours
Duration of Pain Relief
hoursPlaceboCaffeineIbuprofenIbuprofen/Caffeine
Duration of Pain Relief1.63 (1.60 to 2.07)2.08 (1.67 to 3.83)7.11 (6.43 to 7.77)7.33 (7.05 to 7.77)
Statistical analysis
  • Placebo vs Ibuprofen/Caffeine · Log Rank · p = <0.0001Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.
  • Caffeine vs Ibuprofen/Caffeine · Log Rank · p = <0.0001Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.
  • Ibuprofen vs Ibuprofen/Caffeine · Log Rank · p = 0.2389Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.
SecondaryTime to Meaningful Pain Relief

Time to meaningful pain relief was captured by a stopwatch, which was started by the study staff immediately after the administration of the first dose of trial medication and which was to be stopped by the patient as soon as he/she felt meaningful pain relief. Time to meaningful pain relief was censored at 8 hours.

Time frame:
8 hours
Reported as:
Median · hours
Time to Meaningful Pain Relief
hoursPlaceboCaffeineIbuprofenIbuprofen/Caffeine
Time to Meaningful Pain ReliefNA (NA to NA)NA (NA to NA)1.78 (1.48 to 2.02)1.13 (0.93 to 1.35)
Statistical analysis
  • Placebo vs Ibuprofen/Caffeine · Log Rank · p = <0.0001Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.
  • Caffeine vs Ibuprofen/Caffeine · Log Rank · p = <0.0001Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.
  • Ibuprofen vs Ibuprofen/Caffeine · Log Rank · p = 0.0001Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.

Adverse events

Collected over First dose of study drug date/time until drug discontinuation date + 24 hours (inclusive). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/70 (0%)3/70 (4.3%)
Caffeine—0/70 (0%)1/70 (1.4%)
Ibuprofen—1/279 (0.4%)9/279 (3.2%)
Ibuprofen/Caffeine—0/282 (0%)23/282 (8.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboCaffeineIbuprofenIbuprofen/Caffeine
Oral infectionInfections and infestations0/700/701/2790/282
Most frequent other events
Most frequent other events
EventPlaceboCaffeineIbuprofenIbuprofen/Caffeine
NauseaGastrointestinal disorders3/701/709/27923/282

Baseline characteristics

All treated patients

Age, Continuous
Age, Continuous(years)Placebo Stage 1Caffeine Stage 1Ibuprofen Stage 1Ibuprofen/Caffeine Stage 1Total
Mean19.3 ± 1.7719.2 ± 1.7219.6 ± 1.9619.5 ± 2.0619.5 ± 1.95
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Stage 1Caffeine Stage 1Ibuprofen Stage 1Ibuprofen/Caffeine Stage 1Total
Female4639142131358
Male24316782204
Region of Enrollment
Region of Enrollment(participants)Placebo Stage 1Caffeine Stage 1Ibuprofen Stage 1Ibuprofen/Caffeine Stage 1Total
United States7070209213562
08

Study locations

1 site
  • 1335.1.202 Boehringer Ingelheim Investigational Site
    Salt Lake City, Utah, United States
09

References and documents

Publications

  • Forderreuther S, Lampert A, Hitier S, Lange R, Weiser T. The Impact of Baseline Pain Intensity on the Analgesic Efficacy of Ibuprofen/Caffeine in Patients with Acute Postoperative Dental Pain: Post Hoc Subgroup Analysis of a Randomised Controlled Trial. Adv Ther. 2020 Jun;37(6):2976-2987. doi: 10.1007/s12325-020-01297-y. Epub 2020 Apr 24. PubMed 32333328 ↗
  • Weiser T, Richter E, Hegewisch A, Muse DD, Lange R. Efficacy and safety of a fixed-dose combination of ibuprofen and caffeine in the management of moderate to severe dental pain after third molar extraction. Eur J Pain. 2018 Jan;22(1):28-38. doi: 10.1002/ejp.1068. Epub 2017 Aug 14. PubMed 28805281 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2013
First posted
Aug 27, 2013
Start
Aug 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Nov 16, 2016
Last update
Nov 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01929031
Responsible party
Sponsor
First posted
Aug 27, 2013
Start date
Aug 2013
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Nov 16, 2016
Last update
Nov 16, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Caffeine

Start the discussion